Guggenheim analyst Debjit Chattopadhyay lowered the firm’s price target on BioMarin to $120 from $125 and keeps a Buy rating on the shares. Voxzogo outperformance translated into an uptick in its FY23 guidance, notes the firm, which believes improving margins and profitability are likely to be tailwinds as Roctavian "becomes relevant" during the second half of 2023.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMRN:
- BioMarin price target raised to $127 from $112 at Baird
- BioMarin Announces Record Breaking First Quarter 2023 Results, Including 15% Year-over-year Growth of Total Revenues
- BioMarin sees FY23 adjusted EPS $1.80-$2.05, consensus 95c
- BioMarin reports Q1 adjusted EPS 60c, consensus 18c
- William Blair biotech analyst to hold an analyst/industry conference call
